-
Mashup Score: 18Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma During Targeted Therapy - 9 month(s) ago
AbstractPurpose:. FGFR2 fusions occur in 10% to 15% of patients with intrahepatic cholangiocarcinoma (iCCA), potentially benefiting from FGFR inhibitors (FGFRi). We aimed to assess the feasibility of detecting FGFR2 fusions in plasma and explore plasma biomarkers for managing FGFRi treatment.Experimental Design:. We conducted a retrospective study in 18 patients with iCCA and known FGFR2 fusions previously identified in tissue samples from prior FGFRi treatment. Both tissue and synchronous plasma samples were analyzed using a custom hybrid capture gene panel with next-generation sequencing (VHIO-iCCA panel) and validated against commercial vendor results. Longitudinal plasma analysis during FGFRi was performed. Subsequently, we explored the correlation between plasma biomarkers, liver enzymes, tumor volume, and clinical outcomes.Results:. Sixteen patients (88.9%) were positive for FGFR2 fusion events in plasma. Remarkably, the analysis of plasma suggests that lower levels of ctDNA are
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence - PubMed - 1 year(s) ago
Aim: To describe the evolution of regorafenib use, since its approval, in patients with previously treated metastatic colorectal cancer (mCRC) in routine clinical practice in Spain. Methods: We extracted patient characteristics, dosing, safety and efficacy data for the Spanish cohorts …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence https://t.co/iCsqAhnlW6
-
-
Mashup Score: 57Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer - 1 year(s) ago
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer (GC), published in late 2022 and the updated ESMO Gastric Cancer Living Guideline published in July 2023, were adapted in August 2023, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with GC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with GC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), coordinated by ESMO and the Japanese Society of Medical Oncology (JSMO).
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet-
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer - ESMO Open https://t.co/332wOP1qaM
-
-
Mashup Score: 57Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer - 1 year(s) ago
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer (GC), published in late 2022 and the updated ESMO Gastric Cancer Living Guideline published in July 2023, were adapted in August 2023, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with GC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with GC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), coordinated by ESMO and the Japanese Society of Medical Oncology (JSMO).
Source: www.esmoopen.comCategories: General Medicine News, Hem/OncsTweet-
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer - ESMO Open https://t.co/332wOP1qaM
-
-
Mashup Score: 29The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review - 2 year(s) ago
Despite recent molecular and immunological advancements, prognosis of metastatic colorectal cancer (mCRC) patients remains poor. In this context, seve…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
The role of anti-EGFR rechallenge in metastatic colorectal cancer, fro... https://t.co/D6Rd1jr1F6
-
-
Mashup Score: 8ACCP Journals - 2 year(s) ago
Tiragolumab is a first-in-class, fully human IgG1/kappa anti-TIGIT monoclonal antibody that blocks the binding of TIGIT to CD155 (the poliovirus receptor). We summarize the pharmacokinetics (PK) data…
Source: accp1.onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103) - Garralda - The Journal of Clinical Pharmacology - Wiley Online Library https://t.co/T22hUfVlsC
-
-
Mashup Score: 6Methodical Manipulation of the TME in Ovarian Cancer - 2 year(s) ago
Summary. The complex interplay between ovarian cancer cells and the tumor microenvironment (TME) modulates progression, with dynamic cellular interactions influenced by external modulators, including neoadjuvant chemotherapy (NACT). A recent article described the alterations within the TME following NACT, either with or without bevacizumab, in ovarian cancer.See related article by Tavira et al., p. 176
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
RT @CCR_AACR: Methodical Manipulation of the TME in Ovarian Cancer. https://t.co/wQFIOv5SRo https://t.co/EJ2apt210H
-
-
Mashup Score: 24
About 20% of breast and gastric cancers and 3% of colorectal carcinomas overexpress the human epidermal growth factor receptor 2 (HER2) and are sensit…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
RT @ArndtVogel: Targeting HER2 heterogeneity in breast and gastrointestinal cancers @trendscancer https://t.co/RSzpKYT3NC 🧐great review,…
-
-
Mashup Score: 20
In the setting of localized colon cancer (CC), circulating tumor DNA (ctDNA) monitoring in plasma has shown potential for detecting minimal residual d…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
Sequencing paired tumor DNA and white blood cells improves circulating... https://t.co/mViq7oJN47
-
-
Mashup Score: 122
The following ESMO Living Guideline has been recently updated with new treatment recommendations: ESMO Metastatic Colorectal Cancer Living Guideline.1,2
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet-
Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the @myESMO Metastatic Colorectal Cancer Living Guideline - Annals of Oncology https://t.co/BskbYwQVJe
-
RT @ArndtVogel: Clinical Value of Liquid Biopsy in FGFR2+ CCA During Targeted Therapy @CCR_AACR https://t.co/h1zNGe3Upm 👉90% of FGFR2 fusi…